Trial Profile
Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2007
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary) ; Atenolol
- Indications Atherosclerosis; Essential hypertension
- Focus Pharmacodynamics
- Acronyms MORE
- Sponsors Daiichi Sankyo Europe
- 10 Dec 2007 Positive results have been published.
- 05 Nov 2005 New trial record.